Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312.

Cancer research communications - 1 May 2025

Wang Peng, Sun Xin, He Xueting, Kang Di, Liu Xiaoyu, Liu Dan, Li Amin, Yang Guiqun, Lin Yiwei, Li Sujing, Wang Yinxiang, Wang Yanping

Abstract excerpt

SIGNIFICANCE: Glecirasib potently and selectively inhibits KRAS G12C and reduces ERK and AKT phosphorylation in KRAS G12C-mutant cancer cells, further inducing cell-cycle arrest and apoptosis. Glecirasib monotherapy leads to tumor regression in KRAS G12C-mutant animal models and shows synergistic effects with cetuximab or JAB-3312 (sitneprotafib).

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Drug Synergism

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyrimidines

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40304209
DOI: 10.1158/2767-9764.CRC-25-0001
PMCID: PMC12076188

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312.PMID 40304209Read ↗

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.Semantic proximity Read ↗

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.Semantic proximity Read ↗

[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].Semantic proximity Read ↗

Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.Semantic proximity Read ↗

Targeting KRAS G12C with Covalent InhibitorsSemantic proximity Read ↗

Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy.Semantic proximity Read ↗

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.Semantic proximity Read ↗

143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models.Semantic proximity Read ↗

Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer typesSemantic proximity Read ↗

D-1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity.Semantic proximity Read ↗

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors.Semantic proximity Read ↗

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.